We are set to treat Myopia, digitally
Email : email@example.com
Dr. Hamed Bahmani
Founder, Managing Director
Hamed is the founder and managing director of Dopavision. He combines expertise in neuroscience, vision sciences, and engineering with an innovative mindset that drives Dopavision. He has years of experience in academia and industry, and is currently a visiting scholar at the Max Planck Institute for Biological Cybernetics.
Yeshwanth is the product engineer working on devices to realize the Myopia treatment. He has a background in Physics from Jacobs University Bremen and worked for ZEISS Vision Science Lab optics simulation and virtual reality. He is the swiss army knife of Dopavision working on different facets from hardware to research to software.
Co-Founder, Managing Director
Stefan is the co-founder and managing director of Dopavision. He’s an entrepreneur and a former strategy consultant, passionate about developing ideas that make consumers’ and patients’ lives better. He founded Cubitabo, an online retailer for bedroom furniture, and has previously worked at McKinsey&Company.
Tim is the vision scientist at Dopavision. He is interested in color, pupil and brain research in context of visual performance and myopia. He is fascinated by making the world more colorful. He has studied neuroscience as a PhD candidate at the ZEISS Vision Science Lab, Institute of Ophthalmic Research, University Clinic Tübingen and as a guest scientist at the Max Planck Institute for Biological Cybernetics.
Myopia, or near-/short-sightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision.
Dopavision is developing a method to stimulate the brain through the optic nerve to control myopia. Using digital means, MyopiaX® will stimulate the production of dopamine in the retina, which is known to have an impact on eyeball size.